Looking for our Business Solutions? Click here:CloudQuote APIsContact Us
Home

Merck & Co (MRK)

79.29
+1.01 (1.29%)
NYSE · Last Trade: Jun 19th, 5:41 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close78.28
Open78.05
Bid79.00
Ask79.45
Day's Range77.10 - 80.31
52 Week Range73.31 - 134.63
Volume23,803,462
Market Cap200.71B
PE Ratio (TTM)11.54
EPS (TTM)6.9
Dividend & Yield3.240 (4.09%)
1 Month Average Volume13,766,977

Chart

About Merck & Co (MRK)

Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More

News & Press Releases

Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistakebenzinga.com
Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound.
Via Benzinga · June 18, 2025
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yieldsbenzinga.com
Via Benzinga · June 18, 2025
MERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentalschartmill.com
MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors.
Via Chartmill · June 18, 2025
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor.
By Merck & Co., Inc. · Via Business Wire · June 18, 2025
Price Over Earnings Overview: Merck & Cobenzinga.com
Via Benzinga · June 9, 2025
2 Dividend Stocks to Buy and Never Sellfool.com
Via The Motley Fool · June 18, 2025
3 Mega-Cap Stocks with Competitive Advantages
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.
Via StockStory · June 18, 2025
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Billsstocktwits.com
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.
Via Stocktwits · June 17, 2025
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025fool.com
The Dow Jones index could have fared better in May if not for these two stocks.
Via The Motley Fool · June 14, 2025
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgerybenzinga.com
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.
Via Benzinga · June 13, 2025
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullishstocktwits.com
In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said.
Via Stocktwits · June 13, 2025
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
By Merck & Co., Inc. · Via Business Wire · June 13, 2025
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs.
By Merck & Co., Inc. · Via Business Wire · June 12, 2025
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuitbenzinga.com
Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine.
Via Benzinga · June 12, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · June 12, 2025
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore.
By Merck & Co., Inc. · Via Business Wire · June 12, 2025
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatilityfool.com
Via The Motley Fool · June 12, 2025
Unpacking the Latest Options Trading Trends in Merck & Cobenzinga.com
Via Benzinga · June 11, 2025
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?fool.com
Via The Motley Fool · June 11, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · June 10, 2025
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticalschartmill.com
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors.
Via Chartmill · June 10, 2025
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season. ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same 105 mg dose regardless of weight. A typical RSV season usually spans autumn to spring of the next year.
By Merck & Co., Inc. · Via Business Wire · June 9, 2025
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trialsbenzinga.com
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.
Via Benzinga · June 9, 2025
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggishstocktwits.com
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide.
Via Stocktwits · June 9, 2025
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yieldsbenzinga.com
Via Benzinga · June 9, 2025